CRISPR and Drug Development

What Is CRISPR-Cas9?

CRISPR-Cas9 is a molecular scissors system adapted from a bacterial immune defense mechanism. In bacteria, CRISPR sequences store memories of past viral infections, and the Cas9 protein can cut DNA at specific sequences to destroy re-invading viral DNA.

Scientists realized this system could be reprogrammed to cut any DNA sequence: a short RNA molecule (guide RNA) directs Cas9 to the desired location in the genome, and Cas9 makes a precise double-strand cut. The cell then repairs the break — either inactivating the gene (through error-prone repair) or incorporating a new sequence (if a repair template is provided).

Jennifer Doudna and Emmanuelle Charpentier received the 2020 Nobel Prize in Chemistry for this discovery. The ability to edit any genomic sequence with relatively low cost and high precision transformed biomedical research and launched a new era of genetic medicines.

CRISPR as a Drug Platform

As a therapeutic platform, CRISPR edits are made ex vivo (outside the body) or in vivo (inside the body). Current approved therapies use the ex vivo approach:

1. Patient's stem cells (or other relevant cells) are collected.
2. CRISPR editing is performed in the laboratory.
3. Edited cells are reinfused into the patient.

In vivo delivery — injecting the CRISPR machinery directly into the body — is in clinical development but faces greater technical hurdles. Getting Cas9 and guide RNA into the right cell type without triggering an immune response is the central challenge.

Casgevy: The First Approved CRISPR Therapy

In November 2023, Casgevy (exagamglogene autotemcel) became the first CRISPR-based medicine approved by the FDA and UK's MHRA, for sickle cell disease and transfusion-dependent beta-thalassemia.

Both diseases are caused by mutations in the beta-globin gene, which is needed to make adult hemoglobin. Casgevy uses a different approach: instead of correcting the mutant gene, it reactivates a fetal hemoglobin gene (BCH11A) that is normally silenced after birth. Fetal hemoglobin can substitute for adult hemoglobin and does not sickle.

The treatment process: 1. Patient undergoes bone marrow stem cell collection. 2. CRISPR edits the BCH11A gene in those stem cells, reactivating fetal hemoglobin production. 3. Patient undergoes conditioning chemotherapy to clear existing bone marrow. 4. Edited stem cells are reinfused.

In clinical trials, the majority of patients with sickle cell disease had no severe vaso-occlusive crises for at least 12 months after treatment. Most patients with beta-thalassemia became transfusion-independent.

Delivery Challenges

Ex vivo editing works well for diseases involving blood cells because hematopoietic stem cells can be extracted, edited, and reinfused. This approach does not work for diseases of the brain, heart, lungs, or other solid organs where stem cell collection and reinfusion are not feasible.

In vivo CRISPR delivery most commonly uses: - Lipid nanoparticles (LNPs): Deliver mRNA encoding Cas9 + guide RNA; naturally accumulate in the liver, making them suitable for liver-targeted edits. Intellia Therapeutics has Phase 1 data for CRISPR in vivo for transthyretin amyloidosis using LNPs. - Viral vectors: AAV vectors can deliver smaller CRISPR components but have payload size limitations and pre-existing immunity issues. - Direct injection: For localized targets like the eye or inner ear.

Off-Target Editing Safety Concerns

The primary safety concern with CRISPR is off-target editing — unintended cuts at genomic locations that partially resemble the intended target. If an off-target cut occurs near a tumor suppressor gene or oncogene, it could theoretically promote cancer.

Modern guide RNA design algorithms and high-fidelity Cas9 variants (engineered to be more selective) have substantially reduced off-target activity. Clinical trials require whole-genome sequencing of edited cells before reinfusion to verify the editing profile. Long-term follow-up studies are ongoing to detect any delayed adverse effects.

Beyond Sickle Cell: Pipeline

CRISPR therapeutics in clinical development include:

• Transthyretin amyloidosis (ATTR): In vivo LNP-delivered CRISPR to knock out the misfolded transthyretin gene in the liver (Intellia/Regeneron, Phase 3 ongoing).
• Hemophilia A and B: Editing liver cells to produce clotting factors permanently.
• Acute myeloid leukemia: CRISPR-edited CAR-T cells (allogeneic, from donors rather than the patient).
• HIV: Strategies to excise HIV DNA from infected cells are in early development.
• High cholesterol (PCSK9 editing): A single liver edit could permanently lower LDL — trials underway.

Regulatory and Ethical Landscape

Regulatory agencies treat CRISPR therapies as cell and gene therapies, subject to existing biologic drugBiologic Drug

A medication derived from living organisms or their components, including proteins, antibodies, vaccines, and gene therapies. Biologics are larger and more complex than traditional small-molecule drug

frameworks. The approval pathway is the same as for other gene therapies: IND application, phased clinical trials, BLA submission.

The ethical debate distinguishes germline editing (editing embryos or sperm/eggs, which passes changes to all future generations) from somatic editing (editing non-reproductive cells, which affects only the treated individual). All approved and ongoing therapeutic CRISPR applications are somatic. Germline editing in humans remains prohibited by regulatory agencies worldwide, pending resolution of major ethical and safety questions.

Key Takeaways

• CRISPR-Cas9 makes precise cuts in DNA at locations specified by a guide RNA, enabling targeted gene editing.
• Casgevy (2023) is the first approved CRISPR medicine, treating sickle cell disease and beta-thalassemia by reactivating fetal hemoglobin genes.
• Current approved therapies use ex vivo editing of blood stem cells; in vivo delivery for other organs is in development.
• Off-target editing is monitored carefully; high-fidelity Cas9 variants and rigorous screening reduce but do not eliminate this risk.
• A broad pipeline — including cardiovascular, neurological, and infectious disease targets — is progressing through clinical trials.